Tag:

Merck

Latest Headlines

Latest Headlines

Merck attacks Italian critic of cholesterol fighter Zetia, then backs off

In February and again in May, Merck sent a cease-and-desist order to Alberto Donzelli, head of education, appropriateness, and evidence-based medicine at Milan's public health authority. Donzelli had openly criticized Merck's cholesterol-lowering drug Ezetrol (ezetimibe), which is sold in the U.S. as Zetia. Now the company is doing an about-face.

Neuro-stimulator startup electroCore secures Series A expansion to $50M

Investors in migraine device startup electroCore has expanded its Series A round to $50 million. The company initially secured a $40 million tranched round in March 2013. The newly expanded financing comes just as the company prepares to submit its product to the FDA.

Merck takes to Europe with its promising PD-1 cancer drug

Merck is racing to be first on the market among contenders in the PD-1 field of cancer therapy, and the European Medicines Agency has agreed to review its pembrolizumab as a treatment for advanced melanoma.

The top 5 vaccines by 2020

Take a look and at the specifics and check out how the 2020 forecasts stack up to the top 10 best-selling vaccines of 2013.

Merck targets Alzheimer's in $526M collaboration on new cognitive treatment

Last summer, Bionomics struck a $172 million discovery deal on new pain meds with Merck. And now the pharma giant has come back to the bargaining table to bag a much bigger collaboration with the Adelaide, Australia-based biotech, paying $20 million upfront and promising up to $506 million in milestones to collaborate on a new Alzheimer's drug.

Merck JV plans to show up J&J, Sanofi with low-cost cholera vaccine

While the world already has a pair of cholera vaccines that have been proven safe and effective, it lacks a low-cost option that can stay effective without cold storage in impoverished areas where the disease hits hardest. And with a new partnership, that's exactly what Merck's Indian joint venture is looking to change.

Merck, Sanofi JV wins anal cancer indication for Gardasil in EU

Gardasil may be the No. 2-selling vaccine in the world, but its marketers have struggled against a variety of barriers to get it where they want it in terms of uptake. Now, a new anal cancer indication in Europe may help with that goal.

Merck seeks sanctions against Brown U doc over Vioxx comments

David Egilman, a professor of family medicine at Brown University, was once a federal witness in a lawsuit filed against Merck over the now-long-withdrawn Vioxx. Merck finally closed the books on all the Vioxx suits last summer, but the company is now asking a federal judge to sanction Egilman for leaking info to the Wall Street Journal.

What's next in diabetes drugs? The pulse of R&D at ADA14

Convening in San Francisco for the annual conference of the American Diabetes Association this weekend, drugmakers angled for the spotlight in a field made up mostly of similar treatments with small differentiations that could spell the difference between blockbuster sales and also-ran status.

Merck keeps the checkbook open after its $3.9B Idenix deal

Fresh off signing a blockbuster deal for hepatitis C drug developer Idenix Pharmaceuticals, Merck R&D chief Roger Perlmutter said his company won't shy away from buying big into biotech, provided there are promising medicines at stake.